BioInteractions (Booth 1701) is showcasing its newly launched Surface Active Therapeutics, a groundbreaking medical technology poised to revolutionize the safety and efficacy of medical implants, the company says. Surface Active Therapeutic coatings improve how implants interact with the human body, offering enhanced biocompatibility, sustained protection against clinical complications, and improved therapeutic outcomes for the patient that last for the device’s lifetime.
Surface Active Therapeutics are advanced treatments that do not need to release their active ingredients to be effective. These innovative solutions remain effective for extensive periods of time with reduced risks to the patient compared to pharmaceutical coatings that need to be released and have a systemic effect. They are applied directly to the surface of a medical device to help reduce the impact of clinical issues such as thrombosis, fibrin sheath formation or infection.
They provide highly effective and sustained therapeutic benefits to the patient. They use enhanced materials that form a continuous protective shield with active features that are sustained on the surface for years. This shield is made of a polymer matrix, which combines active and passive components to improve the safety of coated implants , enhance the efficacy of the device and elevates the therapeutic benefits to the patient.
“Surface Active Therapeutics represent a paradigm shift for medical implant coating technology,” explains Arjun Luthra, commercial director at BioInteractions. “We’ve developed solutions that don’t just safeguard against complications; they also enhance the performance and longevity of devices and provide long-term therapeutic benefits, fundamentally transforming patient outcomes. Surface Active Therapeutics remain effective throughout an implant’s lifespan and actively interacts with the biology inside the body to avoid the formation of issues like thrombus, fibrin sheath, infections or biofilms, hugely improving patients’ outcomes and quality of life,” he concludes.
